Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

Imatinib mesylate (Gleevec) is effective therapy against Philadelphia chromosome–positive leukemia, but resistance develops in all phases of the disease. Bcr/Abl point mutations and other alterations reduce the kinase inhibitory activity of imatinib mesylate; thus, agents that target Bcr/Abl through...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bartholomeusz, Geoffrey A., Talpaz, Moshe, Kapuria, Vaibhav, Kong, Ling Yuan, Wang, Shimei, Estrov, Zeev, Priebe, Waldemar, Wu, Ji, Donato, Nicholas J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2007
Pynciau:
Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852235/
https://ncbi.nlm.nih.gov/pubmed/17202319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-02-005579
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg